|Bid||4,720.00 x 6100|
|Ask||4,920.00 x 13000|
|Day's range||4,782.00 - 4,886.50|
|52-week range||4,260.00 - 5,520.00|
|PE ratio (TTM)||20.54|
|Earnings date||18 May 2018|
|Forward dividend & yield||2.02 (4.22%)|
|1y target est||75.27|
AstraZeneca, Bristol and Vertex are the likeliest targets of widespread mergers and acquisitions across the biopharma group.
Merck gains priority review for Keytruda in advanced cervical cancer, AbbVie's elagolix meets primary endpoint in second phase III study.
AstraZeneca's (AZN) final overall survival data from the pivotal phase III MYSTIC study on Imfinzi in first line lung cancer to be delayed in the second half of 2018.
Zacks Industry Outlook Highlights: AstraZeneca, Bayer, Dr. Reddy's Laboratories, Teva Pharmaceuticals and Adamas Pharmaceuticals
AstraZeneca Plc delayed the final results from its Mystic lung-cancer trial, which failed last year, to collect more data on how long patients live with and without the company’s treatment.
LONDON (Reuters) - AstraZeneca (AZN.L) now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase ...
AstraZeneca now expects a key lung cancer study of two immunotherapy drugs to produce overall survival results in the second half of 2018, rather than the first half. The Phase III trial, known as Mystic, ...
While the U.S. stock markets appear overheated, savvy investors can find more value in the international markets, particularly Europe, where stocks remain cheap. We asked five top advisors and MoneyShow.com contributors to highlight favorite stocks. They came back with seven picks.
Key announcements include the failure of Dermira's (DERM) acne candidate in two pivotal late-stage studies and Merck's oncology collaboration with Japan's Eisai.
Merck (Jakarta: 28586808.JK - news) & Co Inc and Japan's Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai's cancer drug Lenvima, which is already approved in dozens of countries for two uses. The deal, under which Lenvima will be developed for several types of cancer alone and in combination with Merck (LSE: 0O14.L - news) 's immunotherapy Keytruda, could be worth up to $5.76 billion to Eisai, but most of that would be contingent on eventual sales.
The Zacks Analyst Blog Highlights: United States Steel, Allegheny, Century, Astrazeneca and Ferrari
Drugmakers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world. Studying such real-world evidence offers manufacturers a powerful tool to prove the value of their drugs - something Roche (ROG.S) aims to leverage, for example, with last month's $2 billion (1.46 billion pounds) purchase of Flatiron Health. Real-world evidence involves collecting data outside traditional randomised clinical trials, the current gold standard for judging medicines, and interest in the field is ballooning.
Investors are spinning Viela Bio out of the biologics arm of AstraZeneca PLC and providing the new drug developer with up to $250 million in financing.
AstraZeneca is spinning off six early-stage experimental drugs into a new $250 million standalone biotech company focused on severe autoimmune diseases. The spin-off of the three clinical and three pre-clinical biological compounds, announced on Wednesday, is the latest example of the British drugmaker pruning its non-core drug development work to focus on priority areas, notably in cancer. Chief Executive Pascal Soriot said earlier this month that AstraZeneca had a drug pipeline that was "over-sized relative to the current size of our company".
AstraZeneca Plc is spinning off a company to develop drugs for immune disorders with as much as $250 million from a group of investors.
Key announcements this week included the FDA approval for a second indication of AstraZeneca's (AZN) Imfinzi and an acquisition offer by Merck (MRK).
The latest recommendation follows results from a U.S. study in young children that showed vaccines containing a 2017-2018 strain of H1N1 flu virus performed better than the 2015-2016 strain that had shown decreased effectiveness, AstraZeneca said.
Insulin maker Novo Nordisk (LSE: 0QIU.L - news) said its Ozempic diabetes drug had been included on a list of medicines approved for patients covered by U.S. private health schemes, setting the stage for a battle with Eli Lilly's Trulicity. Novo Nordisk, the world's biggest insulin maker, launched Ozempic, known generically as semaglutide, in the United States this year after it was approved by the U.S. Food and Drug Administration in December. Ozempic is a once-weekly injection that Novo Nordisk hopes will take market share from Trulicity, which has been cutting into sales of Novo Nordisk's once-daily Victoza.
Ionis Pharmaceuticals (IONS) out-licenses Generation 2.5 antisense drug to AstraZeneca under a strategic collaboration agreement.
Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market ...
Data shows that AstraZeneca's (AZN) Imfinzi improved PFS by more than 11 months in comparison to placebo in the concerned patient population.